We are live on ! Find out more
INMB icon

INmune Bio
INMB

41 hedge funds and large institutions have $30.6M invested in INmune Bio in 2021 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

98% more capital invested

Capital invested by funds: $15.5M → $30.6M (+$15.1M)

80% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 10

40% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 5

24% more funds holding

Funds holding: 33 → 41 (+8)

2.9% more ownership

Funds ownership: 8.75% → 11.65% (+2.9%)

7% more call options, than puts

Call options by funds: $1.04M | Put options by funds: $972K

Holders
41
Holders Change
+8
Holders Change %
+24.24%
% of All Funds
0.71%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
7
Reduced
5
Closed
10
Calls
$1.04M
Puts
$972K
Net Calls
+$64K
Net Calls Change
+$64K

Top Buyers

Rank Fund Capital Flow
1
EI
EAM Investors
California
+$2.18M
2
EGI
EAM Global Investors
California
+$1.57M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$889K
4
Janney Montgomery Scott
Janney Montgomery Scott
Pennsylvania
+$773K
5
Citadel Advisors
Citadel Advisors
Florida
+$755K

Top Sellers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
-$1.17M
2
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$536K
3
Millennium Management
Millennium Management
New York
-$499K
4
BlackRock
BlackRock
New York
-$481K
5
HF
HRT Financial
New York
-$262K
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
26
UBS Group
Switzerland
$131K +$55.7K +4,137 +125%
Simplex Trading
27
Simplex Trading
Illinois
$118K +$91.2K +6,766 New
Group One Trading
28
Group One Trading
Illinois
$82K +$63K +4,676 New
ASN
29
Advisory Services Network
Georgia
$55K +$41.9K +3,108 New
Bank of America
30
Bank of America
North Carolina
$30K – – –
TRCT
31
Tower Research Capital (TRC)
New York
$25K -$161K -11,964 -90%
CCM
32
Covington Capital Management
California
$18K – – –
VNA
33
Valley National Advisers
Pennsylvania
$18K +$13.5K +1,000 New
ADL
34
Asset Dedication LLC
California
$14K – – –
FDCDDQ
35
Federation des caisses Desjardins du Quebec
Quebec, Canada
$7.03K – – –
CAPTRUST Financial Advisors
36
CAPTRUST Financial Advisors
North Carolina
$7K +$5.39K +400 New
FIA
37
FNY Investment Advisers
New York
$5K -$79.5K -5,900 -95%
IA
38
IFP Advisors
Florida
$3K – – –
PA
39
Parallel Advisors
California
$2K – – –
Wells Fargo
40
Wells Fargo
California
$1K – – –
Bank of Montreal
41
Bank of Montreal
Ontario, Canada
– -$536K -47,076 Closed
Millennium Management
42
Millennium Management
New York
– -$499K -41,988 Closed
HF
43
HRT Financial
New York
– -$262K -22,055 Closed
ECM
44
ExodusPoint Capital Management
New York
– -$203K -17,073 Closed
SFI
45
Susquehanna Fundamental Investments
Pennsylvania
– -$162K -13,663 Closed
Jane Street
46
Jane Street
New York
– -$145K -12,221 Closed
Citigroup
47
Citigroup
New York
– -$23K -1,908 Closed
Barclays
48
Barclays
United Kingdom
– -$20K -1,667 Closed
IAIM
49
International Assets Investment Management
Florida
– -$12K -700 Closed
SPIA
50
Steward Partners Investment Advisory
New York
– -$5.94K -500 Closed
1
2
3

INMB Hedge Fund Activity: Q2 2021 in Review

41 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in INmune Bio (INMB) for Q2 2021, worth a combined $30.6M — up 98% from $15.5M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new INMB positions and 10 closed out — a net gain of 8 holders — while 7 added to existing stakes and 5 trimmed.

The largest buyer was EAM Investors, opening a new position worth an estimated $2.18M. The largest seller was Ikarian Capital, cutting an estimated $1.17M.

  • 41 institutional investors held INmune Bio (INMB) as of Q2 2021, up from 33 in Q1 2021.
  • Funds reported $30.6M of INmune Bio stock for Q2 2021, up 98% quarter-over-quarter.
  • 18 funds opened new INmune Bio positions in Q2 2021 and 10 closed out, a net change of +8 holders.
  • The largest INmune Bio buyer in Q2 2021 was EAM Investors, an estimated $2.18M added.
  • The largest INmune Bio seller in Q2 2021 was Ikarian Capital, an estimated $1.17M sold.

Based on aggregated 13F filings for Q2 2021.